We are pulmonary hypertension professionals united in our vision for a world without pulmonary vascular disease. We believe we can achieve this together, and we won’t stop until we do.
Drug Discovery and Development Symposium 2025
Full scientific programme is live! With the theme of ‘Inclusive and sustainable drug development for PAH’, the programme is divided into 6 sessions: new standards of care, disease modification, diversity and inclusion, global aspects of drug development and availability, innovations in trial design, and novel drug & device therapies.
PVRI Digital 2025-26 series - submit your webinar proposal
We are delighted to invite our members to submit suggestions for the next PVRI Digital series, which is scheduled to start in September 2025 and will run for 18 months. Find out more and submit your proposal today.
Whether you’re a pulmonary hypertension specialist, a pharmaceutical or industry colleague, a regulator, a patient, or a caregiver, joining our growing global family means you share our vision to reduce the global burden of pulmonary vascular disease.
This year’s symposium will bring together regulatory, industry, and academic bodies in the field, offering a unique platform for in-depth discussions, knowledge exchange, and collaboration on the latest drug advancements in PH. Registration is open.
Presentations: Is there evidence for different phenotypes of PH in ILD? Treatment of pulmonary vascular disease in ILD: as early as possible or only in severe PH?
To study the contribution of QRS prolongation to transplant-free survival, we conducted an observational study of 68 patients with sarcoidosis-related pulmonary hypertension. Every 10-ms increase in QRS interval was associated with an adjusted HR of 1.23 (95% CI: 1.06, 1.44) for the composite outcome of lung transplantation and all-cause mortality.
Pulmonary embolism (PE) is a leading cause of mortality in lung transplant recipients, with early cases associated with particularly poor outcomes. Identified risk factors include elevated BMI, renal dysfunction, ABO mismatch, donor malignancy, and specific immunosuppressive agents. Tailored risk assessments and targeted interventions are essential to mitigating PE-related mortality.
Benchmarks of clinical management are essential for improving the quality of care. However, the lack of established quality metrics for pulmonary arterial hypertension (PAH) contributes to practice heterogeneity. We assessed our center's diagnostic practices, therapeutic practices, and risk-adjusted survival patterns over time for the purpose of establishing quality benchmarks.
We’re pleased to share that the Pulmonary Hypertension Global Patient Survey (PHGPS) - a key project of the IDDI Patient Engagement & Empowerment (PE&E) Workstream - is now a stand-alone Task Force.
We are delighted to invite our members to submit suggestions for the next PVRI Digital series, which is scheduled to start in September 2025 and will run for 18 months.
The PVRI 2025 Annual Congress was hosted in the vibrant city of Rio de Janeiro at the Windsor Convention & Expo Centre. Esteemed experts, healthcare professionals, and researchers from around the globe gathered in this iconic city to share groundbreaking insights, foster collaborations, and advance our collective mission towards conquering PVD.
Rubin Tuder, a trailblazer in the field of pulmonary vascular biology and a driving force in PH research, has been honoured with the PVRI Lifetime Achievement Award for 2025. This prestigious Award is given annually at the PVRI Annual Congress to a senior PH investigator or clinician for their exceptional and outstanding contributions to the field of pulmonary vascular disease and to PVRI. This recognition celebrates his unparalleled contributions to science, mentorship, and the global PH community.
